Healthcare Wire Texas
SEE OTHER BRANDS

Exploring the health and wellness news of Texas

Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on September 3, 2025

Harvard-Trained Founder Wins Global Health Summit Pitch, Redefining Stress Management for the Modern Workforce

Harvard-Trained Founder Wins Global Health Summit Pitch, Redefining Stress Management for the Modern Workforce

AUSTIN, TX, UNITED STATES, September 3, 2025 /⁨EINPresswire.com⁩/ -- From the halls of Harvard to the global stage of the Health Optimisation Summit (HOS), Lupita Almuhana, Founder of Stressie, has claimed top honors as winner of the startup competition at …

Stratilligence Projects Generative BI Market to Reach $90 Billion by 2033 at 46% CAGR

Stratilligence Projects Generative BI Market to Reach $90 Billion by 2033 at 46% CAGR

AI-driven business intelligence tools are set to transform decision-making as Stratilligence projects rapid market growth through 2033. HOUSTON, TX, UNITED STATES, September 3, 2025 /⁨EINPresswire.com⁩/ -- Stratilligence Growth Consultant, a global market …

Splash Tents, Inc. Helps Healthcare Leaders Like Altus Emergency and Baylor Amplify Community Engagement Across Texas

Splash Tents, Inc. Helps Healthcare Leaders Like Altus Emergency and Baylor Amplify Community Engagement Across Texas

Altus Emergency Centers and Baylor Scott …

Molecular Assay Market to Grow at a CAGR of 7% During the Forecast Period (2025 – 2030): Wissen Research

Molecular Assay Market to Grow at a CAGR of 7% During the Forecast Period (2025 – 2030): Wissen Research

Sheridan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global molecular assay market was valued at USD 16.4 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 7% during …

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over  Commercialization and Distribution of Eversense 365

Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference …

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being …

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock

CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares …

Artelo Biosciences Announces Proposed Underwritten Public Offering

Artelo Biosciences Announces Proposed Underwritten Public Offering

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …

DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage …

DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment

DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment

Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une …

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …

Pennant Announces Home Health Acquisition in Wyoming

Pennant Announces Home Health Acquisition in Wyoming

EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that effective September 1, 2025, it …

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that …

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 …

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye …

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of …

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights …

Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC

Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with Novatim Immune Therapeutics (Zhejiang) CO., LTD. , (“ …

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …

Longeveron® Announces Key Leadership Updates

Longeveron® Announces Key Leadership Updates

Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa’el Hashad to step down as CEO and Board member …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions